Bladder sparing: Risk-enabled therapy after initiating neoadjuvant chemo allows active surveillance of some MIBC

Pembrolizumab shows notable antitumour activity for patients with high-risk non–muscle-invasive bladder cancer

Latest in PARP inhibitors and combination therapies for prostate cancer

3 year follow-up of the CheckMate 9ER trial: NIVO + cabozantinib vs sunitinib for first-line treatment of aRCC

Plasma miR371 detects MRD and early relapse of germ cell tumours

Comparative cost-effectiveness of alternative imaging and surveillance schedules for testicular seminoma

Adaptive image-guided radiotherapy in muscle-invasive bladder cancer shows low toxicity and good outcomes

Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC

Final OS results of IMvigor130: Atezolizumab plus platinum/gemcitabine for mUC

Adjuvant nivolumab as standard of care for high-risk muscle-invasive urothelial carcinoma after radical resection

Anti-PSMA antibody radiolabeled with 177Lu improves MFS in high-risk nmCRPC

Erdafitinib demonstrates efficacy in intermediate-risk non–muscle-invasive bladder cancer with FGFR alterations